Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus

Abstract

Get full access to this article

View all access options for this article.

References

Schwartz SA Intravenous immunoglobulin (IVIG) for therapy of autoimmune disorders. J Clin Immunol 1990; 112: 278-280.

Foley-Nolan D. , Gooi HC Current rheumatological uses of intravenous immunoglobulin. Br J Rheumatol 1994; 33: 1002-1006.

Cherin P. et al. Efficacy of intravenous gammaglobulin therapy in chronic refractary polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162-168.

Collet E. et al. Juvenile dermatomyositis: treatment with intravenous gammaglobulin . Br J Dermatol 1994; 130: 231-234.

Messer G. et al. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol 1995; 133: 1014-1015.

Francioni C. et al. Long term IVIG treatment in Systemic Lupus Erythematosus. Clin Ex Rheumatol 1994; 12: 163-168.

Lin CY , Hsu HC , Chan H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gammaglobulin. Nephron 1989; 53: 303-310.